Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,790 Mln
Revenue (TTM)
$9 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.9
Industry P/E
28.17
EV/EBITDA
-5.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$11
EPS
$-3
Face value
--
Shares outstanding
120,520,000
CFO
$-394.43 Mln
EBITDA
$-599.44 Mln
Net Profit
$-586.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Avidity Biosciences - ADR
| 8.1 | -6.5 | 30.4 | -26.1 | 22.6 | 3.1 | -- |
|
BSE Sensex
| 5.4 | 0.1 | 11.7 | 3.2 | 14.8 | 17.7 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Avidity Biosciences - ADR
| 218.3 | -59.2 | -6.6 | -6.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Avidity Biosciences - ADR
|
31.5 | 3,790.4 | 8.9 | -369.2 | -4,861.1 | -26.1 | -- | 2.9 |
| 18.5 | 4,419.0 | 459.4 | 206.8 | 25.6 | 68.3 | 22 | 11.8 | |
| 109.0 | 5,365.8 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 100.9 | |
| 58.1 | 11,142.2 | 2,937.8 | 523.9 | 23.2 | 9.3 | 21.5 | 1.9 | |
| 46.5 | 8,823.8 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 71.9 | 7,622.5 | 685.5 | 132.9 | 15.6 | 20.1 | 62.5 | 11.2 | |
| 14.9 | 7,469.6 | 4,427.0 | 373.0 | -0.7 | 5.8 | 19.9 | 1.2 | |
| 68.6 | 13,277.0 | 4,413.2 | 21.3 | 7.2 | 0.6 | 343 | 3.6 | |
| 76.5 | 3,766.4 | 1,137.8 | 214.6 | 29.2 | 12.3 | 17.8 | 2.1 | |
| 9.1 | 10,704.0 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision... of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Read more
Co-Founder & Chairman
Dr. Troy Edward Wilson J.D., Ph.D.
Co-Founder & Chairman
Dr. Troy Edward Wilson J.D., Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Avidity Biosciences Inc - ADR stood at $ 1,544 Mln as on 31-Mar-25
The share price of Avidity Biosciences Inc - ADR is $31.45 (NASDAQ) as of 11-Jul-2025 16:27 EDT. Avidity Biosciences Inc - ADR has given a return of 22.59% in the last 3 years.
Avidity Biosciences Inc - ADR has a market capitalisation of $ 3,790 Mln as on 11-Jul-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Avidity Biosciences Inc - ADR is 2.85 times as on 11-Jul-2025, a 43% discount to its peers’ median range of 5.04 times.
Since, TTM earnings of Avidity Biosciences Inc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Avidity Biosciences Inc - ADR and enter the required number of quantities and click on buy to purchase the shares of Avidity Biosciences Inc - ADR.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
The CEO & director of Dr. Troy Edward Wilson J.D., Ph.D.. is Avidity Biosciences Inc - ADR, and CFO & Sr. VP is Dr. Troy Edward Wilson J.D., Ph.D..
There is no promoter pledging in Avidity Biosciences Inc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,330
|
|
|
1,144
|
|
|
1,083
|
|
|
873
|
|
|
752
|
|
|
734
|
|
|
553
|
|
|
438
|
|
|
388
|
| Avidity Biosciences Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-26.07
|
|
Operating margin(%)
|
-4861.14
|
|
Net Margin(%)
|
-4136
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Avidity Biosciences Inc - ADR was $0 Mln.
$-0.02
(
